A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung
Latest Information Update: 27 May 2025
At a glance
- Drugs Abenacianine (Primary)
- Indications Lung cancer
- Focus Diagnostic use
- Acronyms VISUALIZE
- Sponsors Vergent Bioscience
Most Recent Events
- 22 May 2025 Primary endpoint has been met. (Measurements taken under SOC surgical procedures and under NIR imaging)
- 22 May 2025 According to a Vergent Bioscience media release, data from this study will be shared in the Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology poster session on Monday, June 2, at 1:30 p.m. CT in Hall A.
- 22 May 2025 Results published in the Media Release